Kenvue CEO Discusses Growth Outlook After J&J Unit Jumps 20% in Market Debut
Johnson & Johnson's consumer-health unit Kenvue made its debut on the New York Stock Exchange and jumped about 20% on Thursday. Thibaut Mongon, CEO of Kenvue, joined Cheddar News to discuss business growth goals and what lies ahead for its well-known pipeline of products, including Band-Aid, Neutrogena, Tylenol, among others.
Stocks were mixed at the open but Wall Street was heading for a losing week as investors digested the hints that the Federal Reserve could raise rates before the end of the year.
Sales of previously occupied U.S. homes fell for the third month in a row in August, as higher mortgage rates, rising prices and a dearth of properties on the market shut out many would-be homebuyers.
